(NASDAQ: ABSI) Absci's forecast annual revenue growth rate of 193.78% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.45%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.33%.
Absci's revenue in 2026 is $1,561,000.On average, 12 Wall Street analysts forecast ABSI's revenue for 2026 to be $684,396,672, with the lowest ABSI revenue forecast at $84,090,865, and the highest ABSI revenue forecast at $3,339,608,635. On average, 12 Wall Street analysts forecast ABSI's revenue for 2027 to be $3,146,028,031, with the lowest ABSI revenue forecast at $184,999,903, and the highest ABSI revenue forecast at $18,311,214,867.
In 2028, ABSI is forecast to generate $7,076,846,930 in revenue, with the lowest revenue forecast at $184,999,903 and the highest revenue forecast at $29,478,138,498.